Autoimmunity Center of Excellence Clinical Research Program

自身免疫卓越中心临床研究计划

• 批准号: 10012466
• 负责人: David Wofsy
• 金额: $ 240.61万
• 依托单位: UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
• 依托单位国家: 美国
• 财政年份: 2014
• 资助国家: 美国
• 起止时间: 2014-05-01 至 2020-04-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10012466
• 关键词: Address; Affect; Antigens; Autoimmune Diseases; Autoimmunity; Autologous; Biological Markers; Blood; Clinical; Clinical Research; Clinical Trials; Cutaneous; Data; Disease; Foundations; Goals; Grant; Immunologic Markers; Immunologics; Immunology; Investigation; Lupus; Lupus Vulgaris; Molecular Biology; Organ; Patients; Pemphigus Vulgaris; Phase; Program Development; Proliferating; Regulatory T-Lymphocyte; Safety; Site; Skin; Systemic Lupus Erythematosus; T-Cell Receptor; Testing; Therapeutic; Tissues; Translating; Treg therapy; Work; base; design; effective therapy; novel; novel strategies; programs

DESCRIPTION (as provided by applicant): This application focuses on the potential for using ex vivo expanded autologous regulatory T cells (Tregs) in the treatment of autoimmune diseases. The central theme is that Tregs provide important protection against autoimmunity. Based on this theme, the central hypothesis is that Treg therapy may be a safe and effective approach to the treatment of diverse autoimmune diseases. To address this hypothesis, we propose two complementary projects. One project will examine Treg therapy in an antigen-non-specific autoimmune disease (systemic lupus erythematosus)(SLE), and one will examine Treg therapy in an antigen-specific autoimmune disease (pemphigus vulgaris)(PV). The selection of these two diseases affords us the following important opportunities: (i) to examine whether this therapeutic approach is generally applicable across clinically distinct autoimmune diseases; (ii) to compare safety, efficacy, and mechanism of action across both antigen-specific and antigen-non-specific autoimmune diseases; (iii) to compare polyclonal and antigen specific Treg therapy in the same disease (PV); and (iv) to examine the same target tissue (skin) in both lupus and PV disease. The specific aims are: Primary Project - Conduct a phase l-ll development program designed to test the feasibility, safety, and potential efficacy of Treg therapy in patients with cutaneous manifestations of lupus. Alternate Project - Conduct a phase l-ll development program designed to compare autologous polyclonal versus enriched antigen-specific Treg therapy in patients with PV. Through these projects, we aim to demonstrate the presence and persistence of transferred Tregs in blood and target tissue; perform T cell receptor sequencing to determine whether infused Tregs proliferate; assess biomarkers in blood and skin; and generate efficacy data to lay the foundation for eventual pivotal trials. RELEVANCE: The broad aim of the UCSF ACE program is to work collaboratively with other ACE sites to translate advances in immunology and molecular biology into practical, safe, and effective therapies for people with autoimmune diseases. Within this umbrella, the UCSF site will focus on examining the prospects of using autologous regulatory T cells as a novel approach to the treatment of autoimmune diseases. By so doing, we will be examining an approach that may have broad applicability across diverse autoimmune diseases.

描述（如申请人所提供的）：本申请集中于使用离体扩增的自体调节性T细胞（T细胞）治疗自身免疫性疾病的潜力。其中心主题是TdR对自身免疫提供重要的保护。基于这一主题，中心假设是Treg疗法可能是治疗多种自身免疫性疾病的安全有效的方法。为了解决这一假设，我们提出了两个互补的项目。一个项目将检查Treg治疗抗原非特异性自身免疫性疾病（系统性红斑狼疮）（SLE），一个项目将检查Treg治疗抗原特异性自身免疫性疾病（寻常天疱疮）（PV）。这两种疾病的选择为我们提供了以下重要机会：（i）检查这种治疗方法是否普遍适用于 本发明的目的是：（i）比较临床上不同的自身免疫性疾病;（ii）比较抗原特异性和抗原非特异性自身免疫性疾病两者的安全性、功效和作用机制;（iii）比较相同疾病（PV）中的多克隆和抗原特异性Treg疗法;以及（iv）检查狼疮和PV疾病两者中的相同靶组织（皮肤）。具体目标是：主要项目-进行I-II期开发计划，旨在测试Treg疗法在具有狼疮皮肤表现的患者中的可行性、安全性和潜在功效。替代项目-进行I-II期开发项目，旨在比较PV患者中自体多克隆与富集抗原特异性Treg疗法。通过这些项目，我们的目标是证明血液和靶组织中转移的T细胞的存在和持久性;进行T细胞受体测序，以确定输注的T细胞是否增殖;评估血液和皮肤中的生物标志物;并生成疗效数据，为最终的关键试验奠定基础。 相关性：UCSF ACE计划的广泛目标是与其他ACE站点合作，将免疫学和分子生物学的进展转化为自身免疫性疾病患者的实用，安全和有效的疗法。在这一保护伞下，UCSF网站将重点研究使用自体调节性T细胞作为治疗自身免疫性疾病的新方法的前景。通过这样做，我们将研究一种可能对多种自身免疫性疾病具有广泛适用性的方法。

项目成果

High-Resolution Analysis of Antibodies to Post-Translational Modifications Using Peptide Nanosensor Microarrays.

• DOI: 10.1021/acsnano.6b03786
• 发表时间: 2016-12-27
• 期刊: ACS nano
• 影响因子: 17.1
• 作者: Lee JR;Haddon DJ;Gupta N;Price JV;Credo GM;Diep VK;Kim K;Hall DA;Baechler EC;Petri M;Varma M;Utz PJ;Wang SX
• 通讯作者: Wang SX

Glucose-regulated protein 78 autoantibody associates with blood-brain barrier disruption in neuromyelitis optica.

• DOI: 10.1126/scitranslmed.aai9111
• 发表时间: 2017-07-05
• 期刊: Science translational medicine
• 影响因子: 17.1
• 作者: Shimizu F;Schaller KL;Owens GP;Cotleur AC;Kellner D;Takeshita Y;Obermeier B;Kryzer TJ;Sano Y;Kanda T;Lennon VA;Ransohoff RM;Bennett JL
• 通讯作者: Bennett JL

Deletional tolerance prevents AQP4-directed autoimmunity in mice.

缺失耐受可防止小鼠 AQP4 导向的自身免疫。

• DOI: 10.1002/eji.201646855
• 发表时间: 2017
• 期刊: European journal of immunology
• 影响因子: 5.4
• 作者: Vogel,Anna-Lena;Knier,Benjamin;Lammens,Katja;Kalluri,SudhakarReddy;Kuhlmann,Tanja;Bennett,JeffreyL;Korn,Thomas
• 通讯作者: Korn,Thomas

Mutations of Recombinant Aquaporin-4 Antibody in the Fc Domain Can Impair Complement-Dependent Cellular Cytotoxicity and Transplacental Transport.

• DOI: 10.3389/fimmu.2018.01599
• 发表时间: 2018
• 期刊: Frontiers in immunology
• 影响因子: 7.3
• 作者: Mader S;Brimberg L;Soltys JN;Bennett JL;Diamond B
• 通讯作者: Diamond B

Human antibodies against the myelin oligodendrocyte glycoprotein can cause complement-dependent demyelination.

• DOI: 10.1186/s12974-017-0984-5
• 发表时间: 2017-10-25
• 期刊: Journal of neuroinflammation
• 影响因子: 9.3
• 作者: Peschl P;Schanda K;Zeka B;Given K;Böhm D;Ruprecht K;Saiz A;Lutterotti A;Rostásy K;Höftberger R;Berger T;Macklin W;Lassmann H;Bradl M;Bennett JL;Reindl M
• 通讯作者: Reindl M